Natera, Inc.는 전 세계적으로 분자 검사 서비스의 개발 및 상용화에 주력하는 진단 기업입니다. 이 회사는 이전에 암 진단을 받은 환자를 대상으로 미세잔존질환(MRD) 평가, 조기 재발 모니터링 및 치료 반응 평가를 위한 맞춤형 ctDNA 혈액 검사인 Signatera; 대장암을 위한 혈액 기반 MRD 검사인 Latitude; 조직 기반의 포괄적인 유전체 프로파일링 검사인 Altera; 그리고 유전성 암 선별 검사인 Empower를 제공합니다. 또한 이 회사는 비침습적 산전 검사인 Panorama; 보인자 선별 검사인 Horizon; 21가지 단일 유전자 유전 질환을 선별하는
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
